1 / 12

Research in the Office of Vaccines Research and Review: Vision and Overview

Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research May 19, 2006. Research in the Office of Vaccines Research and Review: Vision and Overview. Vision for CBER. INNOVATIVE TECHNOLOGY ADVANCING PUBLIC HEALTH

acton-myers
Download Presentation

Research in the Office of Vaccines Research and Review: Vision and Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research May 19, 2006 Research in the Office of Vaccines Research and Review: Vision and Overview

  2. Vision for CBER INNOVATIVE TECHNOLOGY ADVANCING PUBLIC HEALTH • Protect and improve public and individual health in the US and, where feasible, globally • Facilitate the development, approval and access to safe and effective products and promising new technologies • Strengthen CBER as a preeminent regulatory organization for biologics

  3. Products Regulated by CBER • Blood, blood components and derivatives • Vaccines (preventive and therapeutic) • Allergenics • Cell and Gene Therapies • Tissues • Xenotransplantation • Related Devices (including certain IVDs)

  4. CBER 2006-7 Strategic Priorities • Pandemic influenza, emerging infectious disease and counterterrorism preparedness • Enhance product safety through better prevention, detection and response including use of safety teams and modern informatics • Bring safe and effective innovative products to patients efficiently • Improve manufacturing and product quality using 21st century technologies and preventive and risk based approaches

  5. Critical Path Initiative • Identify and focus on regulatory and scientific opportunities to improve product development and availability – consistent with CBER's policy • Opportunity to promote and preserve a science-based CBER and FDA • Seeking input to identify opportunities, collaborators, and priorities • October 2004 workshop • Site visits with advisory committees

  6. Unique Role of FDA Science • FDA scientists are involved in review during product development and see the successes, failures, cross-cutting challenges and missed opportunities • We strive for FDA guidance and policies to be science-based and to foster innovation and improve chances of efficient and successful development of safe and effective products • Scientific expertise is critical to making informed decisions about proposed studies and about the safety and effectiveness of products before and after approval • Unique responsibilities and opportunities

  7. CBER Research Working Group and Leadership Retreat • Consistent with the Critical Path Initiative, CBER RWG developed ideas and principles to strengthen and support CBER science and its alignment and management to our mission • CBER research leadership (including Office Associate Director’s for Research (ADRs) & Directors) held a retreat in September to discuss the input & define next steps • Agreement was reached on: • Guiding Principles for Offices and the Centers • Creation of a CBER Research Leadership Council to Coordinate and Develop Implementing the Principles • Priorities for accomplishment in 2006

  8. Draft Guiding Principles • The CBER research program is highly collaborative and includes laboratory, epidemiological, statistical and clinical sciences. • Its scope will encompass the scientific basis of product innovation, pre-clinical and clinical studies, manufacturing, regulatory submissions, inspections, post-marketing surveillance and guidances. • The research will be high quality, efficient, and directed and managed to provide outcomes that address scientific and regulatory challenges in product development, safety, effectiveness and quality.

  9. Goals of Today’s OVRR Research Program Review • Assess focus, strengths, weaknesses, opportunities, and needs of the OVRR research program as a whole • Assess preparedness for present and future scientific challenges • Make recommendations that help us further dynamic and responsive research intended to facilitate development and evaluation of safe and effective biological products

  10. Objectives of OVRR Research Program Review cont. • Increase visibility and transparency • Communicate how research program is integrated into and with regulatory process • Communicate contributions of OVRR research to product development, quality and availability • Get your input identifying highest needs, where OVRR can best contribute and in prioritizing use of our limited resources • Consider opportunities for redirection, leveraging, new collaborations • Recommendations for attracting (and retaining) qualified experts, who excel in both science and review, for OVRR: who and how best to?

  11. CBER: Innovative Technology Advancing Public Health • CBER has responsibility for some of the most important medical products with major public health and preparedness impacts: blood, vaccines, stem cells and tissues: safety and availability issues • FDA scientific expertise and collaboration can play a critical role in facilitating development of very promising innovative medical products with great potential to contribute to health

  12. Thank you, again! • Expertise, partnership, and wise use of resources are essential • We appreciate and welcome your input and support! • CBER: INNOVATIVE TECHNOLOGY ADVANCING PUBLIC HEALTH

More Related